Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-3 of 3

Sort by

Sort Order Select

Journal Articles

Molecular profile linked to resistance to hypomethilating agents plus venetoclax does not predict outcome in secondary Acute Myeloid Leukemia patients receiving CPX-351 induction.

Carola Riva, Paola Minetto, Giada Zecchetti, Stefano Nicoletta, Ylenia Azzanelli, Roberta Romei, Nicoletta Colombo, Alessia Parodi, Elisabetta Tedone, Enrico Carminati, Francesco Puglisi, Clara Nurra, Giuseppina Fugazza, Paolo Nozza, Michele Cea, Roberto Lemoli, Fabio Guolo

Blood (2025) 146 (Supplement 1): 3402.

https://doi.org/10.1182/blood-2025-3402

Published: 2025

Journal Articles

CPX-351 is effective in secondary Acute Myeloid Leukemia, regardless if defined according to 2016 or 2022 edition of who classification.

Fabio Guolo, Carola Riva, Enrico Carminati, Giada Zecchetti, Stefano Nicoletta, Roberta Romei, Ylenia Azzanelli, Nicoletta Colombo, Sara Rosellini, Alessia Parodi, Elisabetta Tedone, Francesco Puglisi, Clara Nurra, Giuseppina Fugazza, Paolo Nozza, Michele Cea, Roberto Lemoli, Paola Minetto

Blood (2025) 146 (Supplement 1): 1629.

https://doi.org/10.1182/blood-2025-1629

Published: 2025

Journal Articles

Prognostic relevance of mutational profile in secondary Acute Myeloid Leukemia patients treated with CPX-351.

Blood (2025) 146 (Supplement 1): 1623.

https://doi.org/10.1182/blood-2025-1623

Published: 2025